No Picture
News

Viking Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today- New Data from Phase 2 Study of VK2809 Presented at EASL 2019; Results Demonstrate Robust Efficacy at Doses as Low as 5 mg Daily- Phase 2b Study of VK2809 in Biopsy-Confirmed NASH Expected to Commence in… […]